Eli Lilly and Company
LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The compaā¦ read more
Healthcare
Drug ManufacturersāGeneral
53 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$727.21
Price-2.11%
-$15.70
1Y
Price
Market Cap
$688.273b
Large
Price/Earnings 3y Avg5y Avg
47.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+48.2%
EBITDA Margin+36.4%
Net Profit Margin+8.3%
Free Cash Flow MarginRevenue
$53.258b
+18.2%
1y CAGR+23.3%
3y CAGR+17.7%
5y CAGREarnings
$13.800b
+30.3%
1y CAGR+38.8%
3y CAGR+32.1%
5y CAGREPS
$15.30
+30.7%
1y CAGR+40.3%
3y CAGR+33.3%
5y CAGRBook Value
$18.349b
$100.923b
Assets$82.574b
Liabilities$39.904b
DebtDebt to Assets
39.5%
2x
Debt to EBITDAFree Cash Flow
-$50.200m
-112.1%
1y CAGR-55.8%
3y CAGR-45.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company